Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 1826

Next Previous
Drug Profile

SHR 1826

Alternative Names: SHR-1826

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy and adverse event data from a phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 20 Apr 2025 Shandong Suncadia Medicine plans a phase I trial for Liver cancer (Combination therapy, Monotherapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China, in May 2025(NCT06935175)
  • 08 Apr 2025 Shandong Suncadia Medicine plans a phase II trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in China (NCT06915142)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top